CTx1000 designed to clear pathological TDP-43 protein, a central driver of ALS SYDNEY, March 23, 2026 /PRNewswire/ -- Celosia Therapeutics, an Australian biotech company developing advanced gene therapies for neurodegenerative diseases, today announced dosing of the first participant in...
Hence then, the article about celosia therapeutics announces first patient dosed in phase 1b clinical trial of ctx1000 in amyotrophic lateral sclerosis was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Celosia Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of CTx1000 in Amyotrophic Lateral Sclerosis )
Also on site :